ErbB inhibitors (Johnson & Johnson)

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NameErbB inhibitors (Johnson & Johnson)

Drug Alias NameJNJ-28871063JNJ-38480416

ClassificationSmall molecules

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsAnticancer protein kinase inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A